Top ten highlights from the APAC PE, VC, and startup ecosystem this week:
- The Rise of AI and Green Energy: AI reshaped industries, while the global focus shifted to green energy and electric vehicles amid rising temperatures.
- Trump’s Return and Investment Implications: Donald Trump’s return to the White House had implications on investments in China.
- Funding Winter in Southeast Asia: The region faced an unrelenting funding winter, challenging startups.
- Startups Prioritizing Profitability: 2024 saw a push for startups to prioritize profitability over unchecked growth.
- Governance Importance: eFishery, an Indonesian unicorn, suspended its co-founders amidst a financial misreporting investigation, highlighting the need for governance.
- Unicorn Minted in Southeast Asia: A new unicorn emerged in Southeast Asia, while AI and EV startups raised record funding rounds.
- Significant Secondaries Deals in Asia: A look into 2024’s significant secondaries deals in Asia, signaling future trends.
- Big-ticket Transactions in India: India witnessed 32 megadeals worth $6.54 billion, with Zepto’s $665-million fundraising being the largest.
- LP-GP Updates: Notable LP-GP updates included fund closures, investments, and commitments in various regions.
- Startup News and Funding: Key highlights included a unicorn entry in Southeast Asia, major funding rounds, and investments in AI and fintech startups.
APAC Private Markets Research
Explore latest Insights on APAC Private Markets on Smartkarma
Disclaimer:This article by is general in nature and based on publicly available information and not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material. While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars